Circulating tumour DNA technology use in cancer management

27 January 2017

What's important about ctDNA

Cancer incidence is increasing worldwide and in the UK it is estimated that 1 in 2 people born after 1960 will be diagnosed with some form of cancer in their lifetime. New tests that analyse circulating tumour DNA (ctDNA) in the bloodstream of patients with cancer have the potential to transform the management of the disease.

Cancer is a genetic disease and many of the new approaches developed to manage it rely on an understanding of tumour genetics. New therapies are being developed, for a variety of cancers, that target tumours that harbour specific mutations. Read our introductory briefing note to find out more about ctDNA technologies and how they could increase patient access to these new therapies and improve cancer management.

ctDNA technologies are a great example of personalised healthcare in action. Currently ctDNA technologies are being implemented in a small subset of lung cancer patients, potentially opening up the option of new therapies better suited to their tumours. We want to make sure that the healthcare system learns from areas where ctDNA technologies are already being used to ensure it is implemented effectively and efficiently in the future, in order to bring the greatest benefits to patients.

Timeline

  • June 2018

    Consensus statement between CM-Path, Cancer Research UK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8 March 2018. Read news story here.

  • March 2018

    The Cellular Molecular Pathology Initiative (CM-Path) held a symposium on liquid biopsy, which brought together pathologists, oncologists, scientists and pharma to highlight advances in liquid biopsy technologies to the pathology community and how pathologists are integral in intergrating this technology into clinical care. The event was held in association with PHG Foundation and Cancer Research UK.

  • September 2017

    Developed seven recommendations to support the development of effective ctDNA testing services, and published our report Developing effective ctDNA testing services for lung cancer

  • March 2017

    Hosted a multidisciplinary workshop, bringing together clinicians, NHS clinical scientists and the commercial sector, to identify and focus on the most pressing issues affecting the implementation and provision of ctDNA testing services for lung cancer

  • April 2017

    Briefing note: ctDNA technology in cancer: personalised healthcare in action and accompanying blog

  • December 2016

    Briefing note: Circulating tumour DNA technology: the future of cancer management? and accompanying blog

  • May 2016

    What is ctDNA infographic and blog

Our work

We are investigating ctDNA technologies, the cancers in which they could have an impact and the most pressing issues that are affecting implementation of ctDNA testing within the health system.

  • Reviewing the use of ctDNA technologies in lung cancer to inform treatment decisions 
  • Bringing together experts from a wide range of relevant fields, including the laboratories offering testing, to discuss the most pressing issues affecting the widespread implementation of ctDNA testing services in lung cancer
  • Identifying challenges and issues and continuing to support the effective implementation of services

Our position

  • The NHS should consider offering ctDNA testing of EGFR in lung cancer to all eligible patients
  • The NHS should use existing ctDNA testing to maximise access to TKIs
  • There are lessons that can be learned from existing ctDNA services that will support the wider use of ctDNA tests in future

Use #ctDNA to comment on twitter

For more information about this project please contact Dr Laura Blackburn